维药新药治疗骨质疏松症的临床研究指导原则(草案)
2017-10-20阿不都外力阿不都克里木斯拉甫艾白王平山玉苏甫买提努尔
阿不都外力?阿不都克里木++斯拉甫?艾白++王平山++玉苏甫?买提努尔
摘要:本研究针对骨质疏松症维吾尔医诊疗方案进行多中心临床病历回顾性调查,收集患者人口学、诊断学、治疗学、疗效评价、护理学等资料信息,进行整理研究,归纳分析其主症和次症表现,将骨质疏松症分为异常黑胆质型和异常黏液质型,建立骨质疏松症的维吾尔医辨证分型标准。从骨痛、骨密度、生存质量3个方面,并结合临床症状及维吾尔医证候改善情况进行疗效判定。在此基础上,按照国家新药审评的技术要求和程序,研究制定维药新药治疗骨质疏松症的临床研究指导原则(草案)。
关键词:骨质疏松症;维吾尔医药;临床研究指导原则
DOI:10.3969/j.issn.1005-5304.2017.10.001
中图分类号:R291.5;R274.91 文献标识码:A 文章编号:1005-5304(2017)10-0001-04
Clinical Research Guidelines for Treatment of Osteoporosis with New Uyghur Medicine (Draft) Abuduwaili Abudukelimu1, Silafu Aibai2, WANG Ping-shan3, Yusufu Maitinuer1, Muhamaiti Wusiman3, ZHANG Hong3, BAI Lian-sheng3, LI Jin-feng3, LI Zhi-jian2, Abudujilili Abuduaini2, LI Gong-shu4, LIU Bing-lin4, PEI Xiao-jing4, ZHOU Bei4 (1. Xinjiang Uyghur Medicine Hospital, Urumqi 830049, China; 2. Institute of Xinjiang Traditional Uyghur Medicine, Urumqi 830049, China; 3. Xinjiang Uyghur Autonomous Region Food and Drug Administration, Urumqi 830002, China; 4. Center for Drug Evaluation, CFDA, Beijing 100045, China)
Abstract: In this study, retrospective multi-center study on medical records of Uyghur medicine diagnosis and treatment program of osteoporosis was done and demographic, diagnostic, therapeutic, efficacy evaluation and nursing data and other information were collected. The main and secondary disease manifestations of osteoporosis were analyzed inductively. Osteoporosis was divided into 2 types in Uyghur medicine field, which were abnormal Savda type and abnormal Balgham type. Uighur medicine syndrome type standards of osteoporosis were established. Treatment efficacy was evaluated according to bone pain, bone density, life quality, and improvement of clinical symptoms and Uyghur medical symptoms. On this basis, in accordance with the technical requirements of the national drug review, the study developed clinical research guidelines for the treatment of osteoporosis with new Uyghur medicine (draft).
Key words: osteoporosis; Uyghur medicine; clinical research guidelines
骨质疏松症(osteoporosis)是以骨量低下、骨微结构破坏,导致骨脆性增加、易发生骨折为特征的全
基金项目:新疆维吾尔自治区科技计划(201333101)
通讯作者:斯拉甫·艾白,E-mail:aibai@263.net
身性骨病[1-2]。2001年,美國国立卫生研究院(NIH)提出,骨质疏松症是以骨强度下降、骨折风险性增加为特征的骨骼系统疾病。骨强度反映了骨骼的2个主要方面,即骨矿密度和骨质量。该病可发生于不同性别和任何年龄,但多见于绝经后妇女和老年男性。骨质疏松症分为原发性和继发性两大类。原发性骨质疏松症又分为绝经后骨质疏松症(Ⅰ型)、老年性骨质疏松症(Ⅱ型)和特发性骨质疏松(包括青少年型)3种。绝经后骨质疏松症一般发生在妇女绝经后5~10年内;老年性骨质疏松症一般指老人70岁后发生的骨质疏松;……